The investigation began with a human clue. The team analyzed 257 community-dwelling Han Chinese adults aged 50 and older who underwent comprehensive cognitive assessment using the Montreal Cognitive Assessment, a screening tool considered more sensitive than the Mini-Mental State Examination for detecting early deficits. Among a panel of energy metabolism indicators, including blood glucose, creatinine, Klotho, and the albumin/globulin ratio, ghrelin showed the strongest correlation with cognitive scores. Higher circulating ghrelin levels were associated with poorer cognitive performance, and the relationship held after accounting for age, sex, and education. Notably, the association was sex-dependent: women with mild cognitive impairment had significantly higher ghrelin levels than cognitively normal women and than men at the same stage. The authors interpret this elevation not as evidence that ghrelin damages cognition, but as a possible compensatory response to metabolic stress, a biomarker of a brain under siege rather than a culprit.

To test what ghrelin actually does, the researchers turned to two mouse models. The first compared young two-month-old animals with nine-month-old mice, capturing an early stage of natural aging. The second used chronic injection of D-galactose, a sugar that accelerates senescence across tissues and is a widely used chemical model of aging. In both models, behavioral testing revealed clear deficits. In the novel object location and novel object recognition tests, aged and D-galactose-treated mice spent less time exploring objects in new positions or objects they had never seen, indicating impaired spatial and recognition memory. In the Morris water maze, they took longer to find a hidden platform, a classic sign of compromised hippocampal learning.

Beneath these behavioral changes lay a striking cellular signature. Western blotting of hippocampal tissue showed upregulation of the senescence markers p16 and p21 and the DNA damage marker gamma-H2AX, alongside loss of Lamin B1, a nuclear envelope protein that declines as cells age, and reduced HMGB1, a chromatin-associated protein. Immunofluorescence co-localization pinpointed these changes within Iba1-positive microglia in the hippocampal CA1 and CA3 regions, confirming that the brain’s innate immune cells were themselves senescing. At the same time, enzyme-linked immunosorbent assays revealed a flood of inflammatory mediators in the hippocampus, including IL-1alpha, IL-1beta, IL-6, IL-8, CXCL10, MCP1, and M-CSF, an inflammaging profile consistent with the senescence-associated secretory phenotype that aged microglia are known to adopt. Both total and acylated ghrelin were elevated in the plasma of these animals, mirroring the human data.

The therapeutic experiment followed. D-galactose-treated mice received daily ghrelin injections at either 20 or 80 micrograms per kilogram during the final four weeks of aging induction, and the same regimen was applied to naturally aged mice. The results were consistent across both models: ghrelin-treated animals performed significantly better in all three behavioral tests, with the higher dose producing the greatest benefit. Molecular analysis showed that ghrelin suppressed p16, p21, and gamma-H2AX while restoring Lamin B1 and HMGB1, effectively reversing the senescence signature. Immunofluorescence confirmed fewer senescent microglia, and the inflammatory cytokine storm in the hippocampus subsided. Interestingly, the protection extended beyond immune cells, as gamma-H2AX signals in neurons also declined after treatment, though astrocytes showed minimal senescence marker co-localization throughout.

What made this outcome puzzling was the receptor. Ghrelin’s classical receptor, GHSR, was expected to mediate any benefit, yet high-dose ghrelin actually reduced GHSR membrane localization, a sign of receptor desensitization, and only the low dose boosted the p-CaMKII/CaMKII ratio that reflects GHSR-driven synaptic plasticity. Even more tellingly, when the researchers knocked down GHSR in D-galactose-treated primary microglia, ghrelin still suppressed p16, p21, and gamma-H2AX. The anti-senescent effect, in other words, was largely GHSR-independent, pointing to some other molecular intermediary.

To find it, the team deployed network pharmacology, cross-referencing predicted ghrelin targets with genes linked to cognitive impairment and clustering the resulting protein-protein interaction network. Five hub genes emerged: SHBG, SRC, C5AR1, KLF4, and BRCA1. Of these, sex hormone-binding globulin, or SHBG, responded most consistently to ghrelin in vivo. SHBG is classically known as a blood protein that binds sex hormones, but elevated levels have previously been linked to hippocampal atrophy and cognitive decline in clinical studies. Immunofluorescence showed SHBG localized in the cytoplasm of BV2 microglial cells, and molecular docking predicted a physical interaction between ghrelin and SHBG, which co-immunoprecipitation in primary microglia then validated. D-galactose exposure raised hippocampal SHBG, and ghrelin lowered it in a dose-dependent fashion.

The downstream circuit came into focus through transcriptomics and targeted manipulation. RNA sequencing of ghrelin-treated microglia revealed 373 upregulated and 431 downregulated genes, with gene set enrichment analysis positively scoring autophagy pathways. Ghrelin reduced the autophagy substrate p62 while increasing Beclin1 and the LC3-II/LC3-I ratio, hallmarks of enhanced autophagic flux, the cellular recycling process that keeps senescent cells from accumulating damaged components. When the researchers overexpressed SHBG in microglia, the opposite occurred: p62 rose, Beclin1 and LC3 fell, and senescence markers worsened. SHBG knockdown increased JNK1 phosphorylation while SHBG overexpression reduced it, placing JNK1 downstream of SHBG. Blocking JNK1 with a pharmacological inhibitor abolished ghrelin’s ability to raise Beclin1 and LC3, and critically, combining JNK1 inhibition with SHBG overexpression produced no additional suppression, confirming that the two act in a single linear pathway. Finally, forcing Beclin1 expression partially rescued the senescent phenotype caused by SHBG overexpression, completing the picture of a SHBG/JNK1/Beclin1 axis that ghrelin engages to restore autophagy and push microglia back toward a youthful, homeostatic state.

The authors are careful about the limits of their work. The D-galactose and nine-month-old mouse models cannot fully recapitulate human cognitive impairment, the animal experiments used only male mice even though the human data revealed sex-dependent ghrelin patterns, and the long-term safety of ghrelin administration remains untested in larger animals or clinical trials. Some autophagy-related genes, including ERK2, PRKAA1, and CTSD, were untouched by the hormone, suggesting the effect is pathway-specific rather than a blanket activation of the autophagy network. Even so, the study delivers a compelling conceptual advance: a gut-derived metabolic hormone can act on brain immune cells through a non-canonical, receptor-independent route, damping the senescence-associated secretory phenotype that drives neuroinflammation. If the SHBG/JNK1/Beclin1 axis behaves similarly in human microglia, it could open a new class of therapeutic targets for age-related cognitive decline, a condition for which disease-modifying treatments remain desperately lacking despite decades of effort focused almost exclusively on neurons and amyloid.

Subject of Research: Ghrelin regulation of microglial senescence and autophagy in aging-related cognitive impairment

Article Title: Ghrelin Alleviates Aging‐Related Cognitive Impairment by Regulating Autophagy‐Related Signaling via the SHBG/JNK1/Beclin1 Axis in Microglia

Article References: Ghrelin Alleviates Aging‐Related Cognitive Impairment by Regulating Autophagy‐Related Signaling via the SHBG/JNK1/Beclin1 Axis in Microglia. (n.d.). https://doi.org/10.1111/acel.70732

Image Credits: AI Generated

DOI: 10.1111/acel.70732

Keywords: ghrelin, microglia, cognitive impairment, autophagy, SHBG, JNK1, Beclin1, immunosenescence, neuroinflammation, brain aging, D-galactose, Aging Cell

The team began by dissecting the chemistry of the roasted tea. Using colorimetric assays and high-performance liquid chromatography, they quantified the major constituents of the extract. Tea polyphenols dominated at roughly 287 milligrams per gram, followed by catechins at about 138 milligrams per gram, with tea polysaccharides, caffeine, and free amino acids rounding out the profile. Among individual catechins measured against authentic standards, EGCG led at 7.959 milligrams per gram, with catechin, catechin gallate, epigallocatechin, and gallic acid also present in appreciable amounts. Roasting, the authors note, does not merely add flavor; it restructures the active compound inventory, creating the material basis for the tea’s antioxidant, anti-inflammatory, and metabolic effects.

To test whether these compounds could counter aging, the researchers turned to a widely used model in which mice receive daily injections of D-galactose, a sugar that accumulates in tissues and drives oxidative stress, inflammation, and senescence-like damage. Male C57BL/6 mice were divided into four groups of ten: a control group receiving saline, a model group receiving D-galactose alone, and two treatment groups receiving D-galactose plus Nongxiang-type Tieguanyin extract by gavage at either 110 or 550 milligrams per kilogram per day for eight weeks. The doses were not arbitrary. The low dose was scaled from the typical daily tea consumption of Chinese adults, roughly five grams of dry leaves, using standard allometric conversion, while the high dose was set fivefold higher to probe dose dependence.

The behavioral results were striking. D-galactose-treated mice showed sharply reduced endurance on a treadmill, covering less distance before reaching exhaustion, and they faltered earlier on a rotating-rod fatigue test. High-dose tea extract reversed both deficits in a concentration-dependent manner. Grip strength, however, was unaffected, suggesting the compound acts on fatigue and metabolic capacity rather than raw muscle power. Metabolic cage measurements added a circadian dimension: D-galactose suppressed the mice’s 24-hour energy expenditure, with the loss concentrated in the dark phase when rodents are normally most active. High-dose Tieguanyin restored dark-phase energy expenditure to near-normal levels, hinting that the tea helps normalize the daily rhythm of metabolism that frays with age.

The liver emerged as the clear beneficiary. The elevated liver-to-body weight ratio caused by D-galactose fell back toward control values after tea treatment, while the heart, lungs, and kidneys showed no significant changes, indicating a liver-targeted effect. Serum levels of alanine aminotransferase and aspartate aminotransferase, the classic enzymes that spill into blood when hepatocytes are damaged, dropped in treated animals. Inside the liver, the chemical picture shifted just as decisively: levels of the antioxidant enzymes superoxide dismutase and glutathione, depleted by D-galactose, rebounded, while malondialdehyde, a marker of lipid peroxidation, declined. The authors suggest the liver’s own transport machinery may explain this selectivity, since hepatocytes actively take up tea polyphenols through organic anion-transporting polypeptides, concentrating the protective compounds where they are needed most.

Under the microscope, the damage and the rescue were both visible. Hematoxylin-eosin staining revealed that D-galactose had disrupted the architecture of hepatic lobules, disorganized hepatocytes, and loosened cytoplasm, abnormalities that tea treatment largely corrected. Masson staining, which dyes collagen blue, showed extensive fibrous proliferation in the aged livers that receded with treatment, and the fibrosis marker alpha-SMA fell in parallel at the protein level. Senescence itself left a measurable fingerprint: beta-galactosidase staining, a hallmark of senescent cells, lit up the D-galactose livers but faded with tea intervention. Western blotting completed the picture, showing that the senescence drivers P16, P21, and P53, which D-galactose had upregulated, were dialed back, while Sirt1, a longevity-associated deacetylase that D-galactose had suppressed, was restored.

To confirm the effect was not a rodent quirk, the team ran parallel experiments in cultured cells. They induced senescence in AML12 mouse hepatocytes and HepG2 human liver cancer cells using Nutlin-3a, a drug that activates p53-dependent senescence pathways. Co-treatment with the tea extract at one milligram per milliliter significantly reduced p16 and p21 protein levels in both cell lines and cut the fraction of blue-stained, senescence-positive cells. The consistency across mouse and human liver-derived cells strengthens the case that the anti-senescence activity is a genuine biological property of the extract rather than an artifact of one species or one model.

The mechanistic core of the study came from transcriptomics. Sequencing liver RNA revealed 1604 differentially expressed genes between D-galactose and control mice, and 3046 between D-galactose and high-dose tea mice, with 216 genes overlapping. Enrichment analyses converged on a single pathway: NF-κB, the master regulator of inflammatory transcription, was significantly activated by D-galactose and reversed by tea treatment. Gene set enrichment analysis confirmed the pattern, and western blots supplied the protein-level proof. D-galactose specifically increased the phosphorylation of the IKKα/β complex and of the p65 subunit, the molecular switch that releases NF-κB to enter the nucleus and ignite inflammatory gene expression. Tea extract suppressed both phosphorylation events in a dose-dependent fashion, while total protein levels stayed constant.

The authors frame this suppression as a direct counter to inflammaging, the chronic, low-grade inflammation that accompanies aging. Reactive oxygen species generated by dysfunctional mitochondria can activate the IKK complex through upstream kinases such as TAK1, and the tea’s restoration of antioxidant defenses likely starves that cascade of its trigger. The concurrent rise in Sirt1 adds a second brake, since Sirt1 can deacetylate p65 and dampen its transcriptional activity. The researchers are candid about limits: the D-galactose model captures oxidative stress-driven aging rather than the full complexity of natural senescence, and the cell experiments validated the phenotype rather than the upstream NF-κB axis, leaving causal validation for future work with naturally aged animals.

Even so, the translational arithmetic is tantalizing. The low mouse dose corresponds to about five grams of dry roasted Tieguanyin per day for a sixty-kilogram person, squarely within ordinary tea-drinking habits, while the high dose, equivalent to roughly twenty-five grams, could be reached through concentrated extracts or supplements. The authors envision the tea evolving from a traditional beverage into a functional food or anti-aging agent, pending clinical trials to confirm efficacy and optimal dosing in humans. For now, the study delivers something rarer than a health claim: a defined molecular pathway, verified at the levels of behavior, biochemistry, histology, transcriptome, and protein, through which a roasted oolong appears to slow the aging liver’s decline.

Subject of Research: Hepatoprotective and anti-senescence effects of roasted oolong tea extract in a D-galactose mouse aging model mediated by NF-κB pathway inhibition

Article Title: Protective Effects of Nongxiang‐Type Tieguanyin on the Liver of D‐Galactose‐Induced Aging C57BL/6 Mice via the NF‐κB Signaling Pathway

Article References: Chen, W., Li, M., Ye, L., Huang, D., Xiao, J., Sang, Y., Wang, Z., Yang, J., He, C., Chen, J., Zuo, Z., & Chen, X. (2026). Protective Effects of Nongxiang‐Type Tieguanyin on the Liver of D‐Galactose‐Induced Aging C57BL /6 Mice via the NF ‐ κB Signaling Pathway. Food Science & Nutrition, 14(10), Article e72396. https://doi.org/10.1002/fsn3.72396

Image Credits: AI Generated

DOI: 10.1002/fsn3.72396

Keywords: Tieguanyin, oolong tea, NF-κB signaling, liver aging, D-galactose, oxidative stress, cellular senescence, Sirt1, hepatic fibrosis, tea polyphenols, inflammaging, C57BL/6 mice

The research team, led by Ali Reza Malayeri and Seyed Esmaeil Khoshnam, set out to test whether zingerone could counteract the effects of D-galactose, a sugar that has become a standard laboratory tool for modeling aging in animals. When administered in excessive amounts over long periods, D-galactose accumulates in tissues and triggers the formation of reactive oxygen species, advanced glycation end products, and widespread cellular damage. In the brain, this cascade mimics many hallmarks of natural aging, including impaired memory, weakened motor coordination, neuronal loss, and chronic inflammation, which is why the compound is so widely used in preclinical studies of neurodegeneration.

Male Wistar rats were divided into five experimental groups. A control group received only normal saline, while an aging model group received daily subcutaneous injections of D-galactose at a dose of 100 milligrams per kilogram for eight consecutive weeks. Three additional groups received the same D-galactose regimen alongside daily oral doses of zingerone at 5, 10, or 20 milligrams per kilogram delivered by gavage. This design allowed the researchers to examine both whether zingerone had an effect and whether that effect depended on the dose, a critical consideration for any compound being evaluated as a candidate therapeutic agent.

To capture the behavioral consequences of brain aging and any protective action of the compound, the investigators employed a battery of standard tests. The Morris water maze assessed spatial learning and memory by measuring how quickly rats could locate a hidden platform in a pool of opaque water, a task heavily dependent on hippocampal function. The passive avoidance task evaluated the retention of a learned aversive memory. The open field test measured spontaneous locomotor activity and anxiety-like behavior, while the rotarod test assessed balance, coordination, and motor endurance by tracking how long animals could remain on a rotating rod. Together, these assays provided a multidimensional picture of both cognitive and motor function across the experimental groups.

The behavioral results were striking. Rats subjected to D-galactose alone showed the expected pattern of decline: longer times to find the hidden platform, weaker retention of avoidance memories, reduced exploratory locomotion, and shorter latencies before falling from the rotarod. Zingerone treatment, however, significantly reversed these deficits. The compound enhanced cognitive and motor performance across the treatment groups, and the improvements followed a clear dose-response pattern, with the 20 milligrams per kilogram dose producing the strongest protective effects. In the treated animals, spatial memory was sharper, avoidance learning was more robust, and motor endurance was substantially better preserved than in the untreated aging model group.

Beneath these behavioral gains, the biochemical analysis revealed a concurrent restoration of the brain’s redox balance. The researchers examined the oxidative-antioxidative status of the hippocampus, the seahorse-shaped structure essential for forming new memories that is among the first regions affected by aging and neurodegenerative disease. Zingerone treatment reduced lipid peroxidation, the oxidative degradation of membrane lipids that serves as a hallmark of free radical damage, while bolstering the activity of endogenous antioxidant defenses. By replenishing the cellular machinery that neutralizes reactive oxygen species, the compound appears to have interrupted the self-amplifying cycle in which oxidative damage impairs mitochondria, which in turn generate more oxidants.

Equally important was the compound’s impact on neuroinflammation. Chronic activation of inflammatory signaling in the brain, involving pro-inflammatory cytokines and the microglial cells that act as the nervous system’s immune sentinels, is now recognized as a central driver of age-related neurodegeneration. The study found that zingerone significantly reduced inflammatory markers in the hippocampus, suggesting that its antioxidant action extends into the immunological domain. Correlation analyses confirmed a significant association between oxidative stress markers, inflammatory cytokines, and cognitive performance, tying the biochemical improvements directly to the behavioral outcomes and strengthening the causal interpretation that the compound’s protection operates through these two intertwined mechanisms.

Histopathological evaluation reinforced the biochemical and behavioral findings. Qualitative examination of the cortex and hippocampal tissue showed that D-galactose exposure produced visible structural damage to neurons, while zingerone treatment attenuated these changes in a dose-dependent fashion. The preservation of tissue architecture, combined with improved redox status, dampened inflammation, and restored behavior, paints a coherent picture of a compound that protects the aging brain at multiple levels simultaneously, from molecule to cell to whole-animal function.

Zingerone is no stranger to neuroprotective research. It is a smaller, less pungent degradation product of [6]-gingerol and [6]-shogaol, the principal pungent constituents of ginger, and forms when these compounds are heated during cooking. Previous preclinical studies have suggested that zingerone can protect against cognitive deficits in models of cadmium toxicity, status epilepticus, ischemic stroke, and experimental diabetes, and pharmacokinetic work has demonstrated its oral bioavailability in rodents. A recent systematic review of preclinical studies concluded that zingerone holds promise as a neuroprotective agent against cognitive disorders, and studies of ginger constituents have also shown that these small phenolic molecules can cross the blood-brain barrier, a crucial property for any compound intended to act on the central nervous system.

The authors caution that these findings come from a rodent model and that animal results do not automatically translate to humans. D-galactose-induced aging is a useful experimental proxy, but it recapitulates only some aspects of natural human aging, and the doses used in the study far exceed any amount obtainable from dietary ginger. Nonetheless, the study strengthens the rationale for investigating zingerone as a therapeutic or preventive agent for age-related neurobehavioral decline. As natural compounds with potent antioxidant and anti-inflammatory properties continue to attract attention as candidates for healthy aging interventions, this work provides detailed mechanistic evidence that a familiar spice-derived molecule can protect the hippocampus, preserve memory and movement, and potentially blunt the biochemical storm that drives the aging brain toward dysfunction.

Subject of Research: Neuroprotective effects of the ginger-derived compound zingerone in a D-galactose-induced rat model of brain aging

Article Title: Zingerone mitigates cognitive and motor impairments in a D-galactose-induced brain aging model: Role of oxidative stress and neuroinflammation

Article References: Zingerone mitigates cognitive and motor impairments in a D-galactose-induced brain aging model: Role of oxidative stress and neuroinflammation. (n.d.). https://doi.org/10.1007/s11033-026-12748-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12748-0

Keywords: zingerone, ginger, brain aging, D-galactose, oxidative stress, neuroinflammation, hippocampus, cognitive decline, Morris water maze, neuroprotection, antioxidants, Wistar rats